Please select the option that best describes you:
Would you extrapolate OlympiA approach of adjuvant olaparib to HER2-positive disease though trial was performed only in HER2-negative patients?
Patient is otherwise high risk and BRCA+
OlympiA trial: Tutt et al, Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer, NEJM 6/2021